



1-800-533-1710

Platelet Comprehensive Panel, NGS

GNPLT

PATIENT NAME TESTRNV, IMPLEMENTATION				ORDER NUMBER M701000713
PATIENT ID X100407470	DATE OF BIRTH 02/19/1968	AGE 54 Y	SEX Male	REQUESTED BY ATLAS TEST
COLLECTED 2/1/2023, 8:33 AM	RECEIVED 2/2/2023, 1:54 PM	REPORTED 3/1/2023, 1:24 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location. 7028846 MCL RochesterCampus Rochester MN 55901				CLIENT ORDER NUMBER X100407470 CLIENT MRN 321

TEST DESCRIPTION

Evaluation of 70 genes associated with a variety of hereditary platelet disorders.

SPECIMEN

WB Whole Blood

RESULT SUMMARY

Pathogenic Variant Detected

RESULT

Gene (Transcript)	Variant	Zygosity	Classification
WAS NM_000377.3	c.37C>T p.Arg13* ChrX:g.48542279C>T	hemizygous	PATHOGENIC

The following hemizygous PATHOGENIC variant was detected:

WAS (NM_000377.3), chrX(GRCh37):g.48542279C>T, c.37C>T, p.Arg13* (p.R13*)

No additional reportable variants were detected within all other tested genes. See the Genes Analyzed section for a complete list of genes evaluated by this assay.

INTERPRETATION

WAS c.37C>T (p.Arg13*), PATHOGENIC

The hemizygous c.37C>T (p.Arg13*) nonsense variant in the WAS gene (MIM:300392) is classified as pathogenic. Pathogenic variants in the WAS gene have been associated with X-linked recessive Wiskott-Aldrich syndrome. This variant has been reported in many unrelated individuals with a clinical diagnosis of Wiskott Aldrich syndrome (WAS), some with documented reduced/absent WAS protein expression in lymphocytes (1-15). However, functional studies have not been performed to either support or refute the pathogenicity of this variant. This variant is absent from large control databases (16,17). This result is supportive of a diagnosis of Wiskott-Aldrich syndrome for this individual. Clinical correlation is recommended.

This result should be interpreted in the context of clinical findings, family history, and other laboratory testing.

Consultation with a genetics professional is recommended for interpretation of this result and to determine whether reproductive risk assessment and familial testing may be of benefit to this family. Genetic testing for family members is available by ordering FMTT / Familial Mutation, Targeted Testing for the specific variant(s) detected. Please contact the



1-800-533-1710

Platelet Comprehensive Panel, NGS

GNPLT

PATIENT NAME TESTRNV, IMPLEMENTATION				ORDER NUMBER M701000713	
PATIENT ID X100407470	DATE OF BIRTH 02/19/1968	AGE 54 Y	SEX Male	REQUESTED BY ATLAS TEST	
COLLECTED 2/1/2023, 8:33 AM	RECEIVED 2/2/2023, 1:54 PM	REPORTED 3/1/2023, 1:24 PM			
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER X100407470	
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN 321	

laboratory at 1-800-533-1710 or the online test catalog at www.mayocliniclabs.com for information about FMTT.

REFERENCES:

- 1) Jo EK, Futatani T, Kanegane H, et al. Mutational analysis of the WASP gene in 2 Korean families with Wiskott-Aldrich syndrome. *Int J Hematol.* 2003;78(1):40-44. doi:10.1007/BF02983238 (PMID 12894849)
- 2) Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. *Blood.* 2004;104(13):4010-4019. doi:10.1182/blood-2003-05-1592 (PMID 15284122)
- 3) Chien YH, Hwu WL, Ariga T, et al. Molecular diagnosis of Wiskott-Aldrich syndrome in Taiwan. *J Microbiol Immunol Infect.* 2004;37(5):276-281. (PMID 15497008)
- 4) Lutskiy MI, Rosen FS, Remold-O'Donnell E. Genotype-proteotype linkage in the Wiskott-Aldrich syndrome. *J Immunol.* 2005;175(2):1329-1336. doi:10.4049/jimmunol.175.2.1329 (PMID 16002738)
- 5) Wada T, Schurman SH, Garabedian EK, Yachie A, Candotti F. Analysis of T-cell repertoire diversity in Wiskott-Aldrich syndrome. *Blood.* 2005;106(12):3895-3897. doi:10.1182/blood-2005-06-2336 (PMID 16091449)
- 6) Proust A, Guillet B, Picard C, et al. Detection of 28 novel mutations in the Wiskott-Aldrich syndrome and X-linked thrombocytopenia based on multiplex PCR. *Blood Cells Mol Dis.* 2007;39(1):102-106. doi:10.1016/j.bcmd.2007.02.007 (PMID 17400488)
- 7) Lee WI, Yang CY, Jaing TH, Huang JL, Chien YH, Chang KW. Clinical aspects and molecular analysis of Chinese patients with Wiskott-Aldrich syndrome in Taiwan. *Int Arch Allergy Immunol.* 2008;145(1):15-23. doi:10.1159/000107462 (PMID 17703096)
- 8) Gulácsy V, Freiburger T, Shcherbina A, et al. Genetic characteristics of eighty-seven patients with the Wiskott-Aldrich syndrome. *Mol Immunol.* 2011;48(5):788-792. doi:10.1016/j.molimm.2010.11.013 (PMID 21185603)
- 9) Shin CR, Kim MO, Li D, et al. Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome. *Bone Marrow Transplant.* 2012;47(11):1428-1435. doi:10.1038/bmt.2012.31 (PMID 22426750)
- 10) Suri D, Singh S, Rawat A, et al. Clinical profile and genetic basis of Wiskott-Aldrich syndrome at Chandigarh, North India. *Asian Pac J Allergy Immunol.* 2012;30(1):71-78. (PMID 22523910)
- 11) Bai X, Zhang Y, Huang L, et al. The early activation of memory B cells from Wiskott-Aldrich syndrome patients is suppressed by CD19 downregulation [published correction appears in *Blood.* 2019 Nov 28;134(22):1997]. *Blood.* 2016;128(13):1723-1734. doi:10.1182/blood-2016-03-703579 (PMID 27330000)
- 12) Ferrua F, Cicalese MP, Galimberti S, et al. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. *Lancet Haematol.* 2019;6(5):e239-e253. doi:10.1016/S2352-3026(19)30021-3 (PMID 30981783)
- 13) Haskoloğlu Ş, Öztürk A, Öztürk G, et al. Clinical Features and Outcomes of 23 Patients with Wiskott-Aldrich Syndrome: A Single-Center Experience. *Turk J Haematol.* 2020;37(4):271-281. doi:10.4274/tjh.galenos.2020.2020.0334 (PMID 32812413)
- 14) Zhu Q, Zhang M, Blaese RM, et al. The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene. *Blood.* 1995;86(10):3797-3804. (PMID 7579347)
- 15) Remold-O'Donnell E, Cooley J, Shcherbina A, et al. Variable expression of WASP in B cell lines of Wiskott-Aldrich syndrome patients. *J Immunol.* 1997;158(9):4021-4025. (PMID 9126958)
- 16) dbSNP: www.ncbi.nlm.nih.gov/snp; Sherry ST, Ward M and Sirotkin K. dbSNP-Database for Single Nucleotide Polymorphisms and Other Classes of Minor Genetic Variation. *Genome Res.* 1999;9:677-679 (PMID 10447503)



1-800-533-1710

Platelet Comprehensive Panel, NGS

GNPLT

PATIENT NAME TESTRNV, IMPLEMENTATION					ORDER NUMBER M701000713
PATIENT ID X100407470	DATE OF BIRTH 02/19/1968	AGE 54 Y	SEX Male	REQUESTED BY ATLAS TEST	
COLLECTED 2/1/2023, 8:33 AM	RECEIVED 2/2/2023, 1:54 PM	REPORTED 3/1/2023, 1:24 PM			
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER X100407470	
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN 321	

17) gnomAD Browser: gnomad.broadinstitute.org/; Karczewski K, Francioli LC, MacArthur DG, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020; 581(7809):434-443 (PMID 32461654)

METHOD

Next generation sequencing (NGS) and/or Sanger sequencing was performed to test for the presence of variants in coding regions and intron/exon boundaries of the genes analyzed, as well as some other regions that have known pathogenic variants. NGS and/or a polymerase chain reaction (PCR)-based quantitative method was performed to test for the presence of deletions and duplications in the genes analyzed. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth over 30X. Sensitivity is estimated at above 99% for single nucleotide variants, above 94% for indels less than 40 base pairs (bp), above 95% for deletions up to 75 bp and insertions up to 47 bp. See the Genes Analyzed field for a list of genes tested.

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria. See www.mayocliniclabs.com (TEST ID GNPLT) for details regarding genes with regions not routinely covered.

GENES ANALYZED

ABCC4, ABCG5, ABCG8, ACTB, ACTN1, ANKRD26, ANO6, AP3B1, AP3D1, ARPC1B, BLOC1S3, BLOC1S5, BLOC1S6, CDC42, CYCS, DIAPH1, DTNBP1, ETV6, FERMT3, FLI1, FLNA, FYB1, GATA1, GATA2, GF11B, GNE, GP1BA, GP1BB, GP6, GP9, HOXA11, HPS1, HPS3, HPS4, HPS5, HPS6, IKZF5, ITGA2B, ITGB3, KDSR, LYST, MASTL, MECOM, MPIG6B, MPL, MYH9, NBEA, NBEAL2, ORAI1, P2RY1, P2RY12, PLA2G4A, PLA2G4B, PRKACG, PTGS1, RASGRP2, RBM8A, RUNX1, SLFN14, SRC, STIM1, STXBP2, TBXA2R, TBXAS1, THPO, TPM4, TUBB1, VIPAS39, VPS33B and WAS

DISCLAIMER

Clinical Correlations

An online research opportunity called GenomeConnect (genomeconnect.org), a project of ClinGen, is available for the recipient of this genetic test. This patient registry collects de-identified genetic and health information to advance the knowledge of genetic variants. Mayo Clinic is a collaborator of ClinGen. This may not be applicable for all tests.

If testing was performed because of a clinically significant family history it is often useful to first test an affected family member. Detection of a reportable variant(s) in an affected family member would allow for more informative testing of at risk individuals.



1-800-533-1710

Platelet Comprehensive Panel, NGS

GNPLT

PATIENT NAME TESTRNV, IMPLEMENTATION					ORDER NUMBER M701000713
PATIENT ID X100407470	DATE OF BIRTH 02/19/1968	AGE 54 Y	SEX Male	REQUESTED BY ATLAS TEST	
COLLECTED 2/1/2023, 8:33 AM	RECEIVED 2/2/2023, 1:54 PM	REPORTED 3/1/2023, 1:24 PM			
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER X100407470	
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN 321	

To discuss the availability of further testing options or for assistance in the interpretation of these results, Mayo Clinic Laboratory genetic counselors can be contacted at 1-800-533-1710.

Technical Limitations

Next generation sequencing may not detect all types of genomic variants. In rare cases, false negative or false positive results may occur. The depth of coverage may be variable for some target regions, but assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria.

Additionally, low level mosaic variants may not be detected.

This test is not designed to differentiate between somatic and germline variants. If there is a possibility that any detected variant is somatic, additional testing may be necessary to clarify the significance of results.

Genes may be added or removed based on updated clinical relevance. Please refer to the Targeted Genes and Methodology Details for the Platelet Comprehensive Panel, NGS in the Special Instructions section of the Test Catalog for the most up to date list of genes included in this test.

Reclassification of Variants Policy

See www.mayocliniclabs.com (TEST ID GNPLT) for information regarding the laboratory's policy for reclassification of variants.

Variant Evaluation

Variant curation is performed using published ACMG-AMP recommendations as a guideline. Other gene-specific guidelines may also be considered. Variants classified as benign or likely benign are not reported.

Results from in silico evaluation tools may change over time and should be interpreted with caution and professional clinical judgment.

TEST CLASSIFICATION

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

RELEASED BY

SHANDA VOELTZ



1-800-533-1710

Platelet Comprehensive Panel, NGS

GNPLT

PATIENT NAME TESTRNV, IMPLEMENTATION					ORDER NUMBER M701000713
PATIENT ID X100407470	DATE OF BIRTH 02/19/1968	AGE 54 Y	SEX Male	REQUESTED BY ATLAS TEST	
COLLECTED 2/1/2023, 8:33 AM	RECEIVED 2/2/2023, 1:54 PM	REPORTED 3/1/2023, 1:24 PM			
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER X100407470	
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN 321	

Code : MCR Laboratory : Mayo Clinic Laboratories - Rochester Main Campus
Lab Director : WILLIAM MORICE MD, PHD CLIA Certificate : 24D0404292

Address : 200 FIRST STREET SW
ROCHESTER MN 55905